Does Cefepime Cover Pseudomonas aeruginosa?
Yes, cefepime provides excellent coverage against Pseudomonas aeruginosa and is specifically FDA-approved for treating moderate to severe pneumonia, complicated intra-abdominal infections, and other serious infections caused by this organism 1.
FDA-Approved Indications
Cefepime is explicitly indicated for infections caused by P. aeruginosa, including:
- Pneumonia (moderate to severe), including cases with concurrent bacteremia 1
- Complicated intra-abdominal infections (when combined with metronidazole) 1
- Urinary tract infections when severe 1
Guideline Support for Antipseudomonal Activity
The 2016 IDSA/ATS hospital-acquired pneumonia guidelines consistently list cefepime as a first-line antipseudomonal agent across all risk categories 2:
- Standard dosing: 2 g IV every 8 hours
- Listed alongside other antipseudomonal agents (piperacillin-tazobactam, ceftazidime, carbapenems, fluoroquinolones)
- Recommended for both monotherapy in lower-risk patients and as part of combination therapy in high-risk patients or those with structural lung disease
When treating P. aeruginosa pneumonia specifically, the FDA label recommends 2 g IV every 8 hours 1, which aligns with guideline recommendations.
Microbiological Activity
Cefepime demonstrates robust in vitro activity against P. aeruginosa:
- Comparable activity to ceftazidime, the traditional antipseudomonal cephalosporin 3, 4
- Stable against many beta-lactamases and a poor inducer of AmpC beta-lactamases 3
- In one ICU study, cefepime inhibited 93% of all isolates tested, including excellent activity against P. aeruginosa 4
Critical Dosing Considerations for Pseudomonas
The standard 4 g/day dosing (1 g every 6 hours or 2 g every 12 hours) may be insufficient for P. aeruginosa infections—higher doses are often necessary:
Pharmacodynamic Targets
- Cefepime requires >60% fT>MIC (time above MIC) for optimal microbiological response against P. aeruginosa 5
- Patients with fT>MIC ≤60% were 8.1 times more likely to experience microbiological failure 5
Optimal Dosing Strategies
For normal renal function (CrCl >60 mL/min):
- Minimum effective dose: 2 g every 8 hours (6 g/day total) 1, 5, 6
- Extended infusion: 2 g over 3-4 hours every 8 hours provides superior outcomes 7
- One study showed mortality reduction from 20% to 3% (p=0.03) with extended infusion versus standard 30-minute infusion 7
Critical evidence: A 2025 retrospective study found that cefepime 4 g/day (1 g every 6 hours) resulted in 44% mortality compared to only 9% mortality with 6 g/day (2 g every 8 hours) in P. aeruginosa bacteremia (p<0.05) 8.
Renal Adjustment
For patients on renal replacement therapy, dosing varies 9:
- CVVH: 2000 mg every 12 hours
- Intermittent hemodialysis: 1000 mg every 24 hours
- These adjusted doses achieved 72.7% 30-day survival in P. aeruginosa infections
Important Caveats
Resistance Concerns
- Treatment-emergent resistance has been documented, with MICs increasing from 8/8 to 32/32 mg/L during therapy, associated with clinical failure 10
- Resistance can develop through MexAB-OprM efflux pump mutations, causing cross-resistance to other beta-lactams 10
When to Use Combination Therapy
The IDSA/ATS guidelines recommend two antipseudomonal agents when 2:
- High risk of mortality (septic shock, need for mechanical ventilation)
- Structural lung disease (bronchiectasis, cystic fibrosis)
- Recent IV antibiotic use within 90 days
- High local resistance rates
MIC Considerations
- Cefepime maintains activity against P. aeruginosa with MICs up to 8 mg/L when using optimal dosing 5, 11
- For MICs >8 mg/L, consider alternative agents or combination therapy
- Always obtain susceptibility testing when possible
Clinical Bottom Line
Cefepime definitively covers P. aeruginosa, but success depends on adequate dosing: use 2 g IV every 8 hours (6 g/day total), preferably as an extended 3-4 hour infusion, especially for serious infections like pneumonia or bacteremia. The commonly used 4 g/day dosing is associated with significantly higher mortality and should be avoided for pseudomonal infections in patients with normal renal function.